De Giglio, A.; Lamberti, G.; Facchinetti, F.; Genova, C.; Andrini, E.; Dal Bello, M. G.; Tiseo, M.; Metro, G.; Chiari, R.; Ricciuti, B., Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib, «CLINICAL LUNG CANCER», 2020, 21, pp. 478 - 487 [Scientific article]
Cortellini, A.; Bersanelli, M.; Buti, S.; Cannita, K.; Santini, D.; Perrone, F.; Giusti, R.; Tiseo, M.; Michiara, M.; Di Marino, P.; Tinari, N.; De Tursi, M.; Zoratto, F.; Veltri, E.; Marconcini, R.; Malorgio, F.; Russano, M.; Anesi, C.; Zeppola, T.; Filetti, M.; Marchetti, P.; Botticelli, A.; Antonini Cappellini, G. C.; De Galitiis, F.; Vitale, M. G.; Rastelli, F.; Pergolesi, F.; Berardi, R.; Rinaldi, S.; Tudini, M.; Silva, R. R.; Pireddu, A.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Iacono, D.; Gelibter, A.; Occhipinti, M. A.; Parisi, A.; Porzio, G.; Fargnoli, M. C.; Ascierto, P. A.; Ficorella, C.; Natoli, C., A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2019, 7, Article number: 57 , pp. 1 - 11 [Scientific article]Open Access
de Giglio, A.; Nuvola, G.; Gustavo Dall'Olio, F., Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies, «TRANSLATIONAL CANCER RESEARCH», 2019, 8, pp. 18 - 23 [Scientific article]Open Access
Ricciuti, B.; Genova, C.; De Giglio, A.; Bassanelli, M.; Dal Bello, M. G.; Metro, G.; Brambilla, M.; Baglivo, S.; Grossi, F.; Chiari, R., Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2019, 145, pp. 479 - 485 [Scientific article]
Boni, A.; Cochetti, G.; Sidoni, A.; Bellezza, G.; Lepri, E.; De Giglio, A.; Turco, M.; Vermandois, J. A. R. D.; Zingaro, M. D.; Cirocchi, R.; Mearini, E., Primary angiosarcoma of the kidney: Case report and comprehensive literature review, «OPEN MEDICINE», 2019, 14, pp. 443 - 455 [Scientific article]Open Access
Verzoni, E.; Carteni, G.; Cortesi, E.; Giannarelli, D.; De Giglio, A.; Sabbatini, R.; Buti, S.; Rossetti, S.; Cognetti, F.; Rastelli, F.; Sobrero, A.; Turci, D.; Sternberg, C. N.; Porta, C.; Cappuzzo, F.; Tortora, G.; Tassinari, D.; Panni, S.; Pazzola, A.; Surico, G.; Raimondi, A.; De Giorgi, U.; Procopio, G., Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2019, 7, Article number: 99 , pp. 1 - 9 [Scientific article]Open Access
Abu-Sbeih, H.; Ali, F. S.; Naqash, A. R.; Owen, D. H.; Patel, S.; Otterson, G. A.; Kendra, K.; Ricciuti, B.; Chiari, R.; De Giglio, A.; Sleiman, J.; Funchain, P.; Wills, B.; Zhang, J.; Naidoo, J.; Philpott, J.; Gao, J.; Subudhi, S. K.; Wang, Y., Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis, «JOURNAL OF CLINICAL ONCOLOGY», 2019, 37, pp. 2738 - 2745 [Scientific article]Open Access
Ricciuti, B.; Genova, C.; Bassanelli, M.; De Giglio, A.; Brambilla, M.; Metro, G.; Baglivo, S.; Dal Bello, M. G.; Ceribelli, A.; Grossi, F.; Chiari, R., Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression, «CLINICAL LUNG CANCER», 2019, 20, pp. 178 - 185 [Scientific article]
Ricciuti, B.; Baglivo, S.; De Giglio, A.; Chiari, R., Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience, «THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE», 2018, 12, Article number: 1753466618808659 , pp. 1 - 13 [Scientific article]Open Access
Baglivo, S.; Ricciuti, B.; Ludovini, V.; Metro, G.; Siggillino, A.; De Giglio, A.; Chiari, R., Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation, «JOURNAL OF THORACIC ONCOLOGY», 2018, 13, pp. 145 - 147 [Scientific article]
De Giglio, A.; Porreca, R.; Brambilla, M.; Metro, G.; Prosperi, E.; Bellezza, G.; Pirro, M.; Chiari, R.; Ricciuti, B., Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?, «THROMBOSIS RESEARCH», 2018, 163, pp. 51 - 53 [Scientific article]
Ricciuti, B.; De Giglio, A.; Mecca, C.; Arcuri, C.; Marini, S.; Metro, G.; Baglivo, S.; Sidoni, A.; Bellezza, G.; Crino, L.; Chiari, R., Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib, «MEDICAL ONCOLOGY», 2018, 35, Article number: 72 , pp. 1 - 18 [Scientific article]
Ricciuti, B.; Baglivo, S.; Paglialunga, L.; De Giglio, A.; Bellezza, G.; Chiari, R.; Crino, L.; Metro, G., Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2017, 9, pp. 387 - 403 [Scientific article]Open Access
Ricciuti, B.; Leonardi, G. C.; Ravaioli, N.; De Giglio, A.; Brambilla, M.; Prosperi, E.; Ribacchi, F.; Meacci, M.; Crino, L.; Maiettini, D.; Chiari, R.; Metro, G., Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient, «JOURNAL OF BREAST CANCER», 2016, 19, pp. 324 - 329 [Scientific article]
